BJMO - volume 13, issue 2, march 2019
L. Decoster MD, PhD, H. Rouvière MD, C. Kenis PhD
The 2018 annual conference of the International Society of Geriatric Oncology took place in Amsterdam, the Netherlands from November 16–18th. More than 500 delegates from 41 countries with a special interest in the care for older patients with cancer attended this conference. The meeting provided an overview of current advances in geriatric oncology.
(BELG J MED ONCOL 2019;13(2):60–62)
Read moreBJMO - volume 12, issue 3, may 2018
L. Decoster MD, PhD, H. Rouvière MD, C. Kenis PhD
The 2017 annual conference of the International Society of Geriatric Oncology took place in Warsaw, Poland from November 9–11th. More than 300 delegates from 42 countries with a special interest in the care for older patients with cancer attended this conference. The meeting provided an overview of current advances in geriatric oncology.
(BELG J MED ONCOL 2018:12(3):142–144)
Read moreBJMO - volume 11, issue 8, december 2017
L. Decoster MD, PhD, K. Vekens , S. Mignon , D. Schallier MD, PhD, J. De Grève MD, PhD
Antibodies against programmed cell death-1 (PD-1) and its ligand (PD-L1) have become standard-of-care in the second-line treatment for advanced non-small cell lung cancer after failure of first-line chemotherapy. The observed durable responses as well as the favourable toxicity profile have moved these agents to first-line studies for advanced non-small cell lung cancer. In tumours with high PD-L1 expression, pembrolizumab is registered as the preferred first-line treatment. Further studies are currently focusing on combination strategies. The major future challenge will be selecting the optimal treatment strategy for the patient.
(BELG J MED ONCOL 2017;11(8):380–385)
Read moreBJMO - volume 11, issue 2, march 2017
L. Decoster MD, PhD, C. Kenis PhD
The 2016 annual conference of the International Society of Geriatric Oncology took place in Milan, Italy from November 17–19th. More than 450 delegates from 42 countries with a special interest in the care for older patients with cancer attended this conference. The meeting provided an overview of current advances in geriatric oncology.
(BELG J MED ONCOL 2017;11(2):78–80)
Read moreBJMO - 2017, issue 3, february 2017
R.B. Shahi MSc, B. Caljon , S. De Brakeleer PhD, L. Decoster MD, PhD, C. Fontaine MD, L. Vanacker MD, M. Vanhoeij , I. Pauwels , M-L. Bonduelle , S. Van Dooren PhD, D. Croes , E. Teugels PhD, J. De Grève MD, PhD
BJMO - 2017, issue 3, february 2017
L. Decoster MD, PhD, C. Kenis PhD, J. Flamaing , P.R. Debruyne , I. De Groof , C. Focan MD, PhD, F. Cornélis MD, V. Verschaeve , K. Vanoverbeke , Y. Libert , S. Luce , N. Nols , H. van den Bulck , J.C. Goeminne MD, K. Geboers , J.P. Lobelle , M. Lycke , K. Milisen , H. Wildiers MD, PhD, A. Baitar
BJMO - volume 10, issue 7, november 2016
J. De Grève MD, PhD, L. Decoster MD, PhD, R.B. Shahi MSc, C. Fontaine MD, L. Vanacker MD, I. Pauwels , E. Denayer MD, PhD, S. De Brakeleer PhD, E. Teugels PhD
Inhibition of Poly (ADP-ribose) polymerase 1 has relatively recently entered the clinic. The ground-breaking drug both scientifically and clinically was olaparib, but several other PARP inhibitors are in development. This treatment is the first to therapeutically exploit mutant recessive cancer genes. In this review we discuss the discovery of this treatment, the preclinical and clinical studies, as well as some future perspectives.
(BELG J MED ONCOL 2016;10(7):263–275)
Read more
Top
